The maintenance of a Buy rating by HC Wainwright & Co. suggests a positive outlook on CARISMA Therapeutics' future performance. However, the reduction in the price target from $9 to $8 may reflect a reassessment of near-term growth expectations or market conditions, potentially leading to a neutral short-term impact on the stock price. The analyst's decision to lower the price target could be based on various factors, including market trends, recent company performance, or changes in the competitive landscape, which are not specified in the news.